ESMO HIGHLIGHTS 2024 – GU ROUNDTABLE DISCUSSION: Bladder
OR
Chapter selection available inside video player. Click here for outline.
01:06
LBA5 A randomized phase 3 trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA)
11:29
1961O Nivolumab plus chemoradiotherapy in patients with non-metastatic muscle-invasive bladder cancer (nmMIBC), not undergoing cystectomy: a phase II, randomized study by the Hellenic GU Cancer Group.
21:39
LBA84 TAR-200 plus cetrelimab (CET) or CET alone as neoadjuvant therapy in patients (pts) with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy (NAC): interim analysis of SunRISe-4 (SR-4)
Chair
Dr. Christian Kollmannsberger
Panelists
Dr. Maria Jiang
Dr. Sebastian Hotte
